GSK plc (NYSE:GSK) is one of the 12 best healthcare stocks to buy now. On June 12, the company announced licensing its ...

This collaboration reflects Bharat Biotech’s continued commitment to global public health and equitable vaccine access ...

GSK has licensed its shigella vaccine candidate to Bharat Biotech. The Big Pharma, which has vowed to help Bharat with trial ...

Under terms of the deal, Bharat Biotech will lead late-stage development and scale-up of the altSonflex1-2-3 Shigella vaccine ...

Bharat Biotech joins GSK to develop a Shigella vaccine to fight shigellosis in children, with Phase 3 trials underway and ...

UK pharma major GSK today revealed that it has licensed its Shigella vaccine candidate, altSonflex1-2-3, to India’s Bharat ...

India also impacted by Shigellosis, a severe form of bacterial diarrhoea that disproportionately affects children under five in low- and middle-income countries ...

Bharat Biotech has in-licensed GSK's Shigella vaccine candidate, altSonflex1-2-3, aimed at combating Shigellosis in young ...

Hyderabad-based Bharat Biotech will lead Phase 3 trials, regulatory progress and manufacturing for Shigella vaccine ...

Bharat Biotech and GSK collaborate to advance Shigella vaccine, aiming to combat urgent public health threat globally.

Hyderabad: Vaccine maker Bharat Biotech International Limited (BBIL) has in-licensed pharma giant GSK's under development ...

GSK said it licensed its Shigella vaccine candidate, altaltSonflex1-2-3, to Bharat Biotech International.